The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.25
Bid: 19.00
Ask: 19.50
Change: -0.25 (-1.28%)
Spread: 0.50 (2.632%)
Open: 19.50
High: 19.50
Low: 18.50
Prev. Close: 19.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Geomerics Real-Status deal

1 Mar 2011 07:00

RNS Number : 0271C
Angle PLC
01 March 2011
 



 

 

For immediate release

1 March 2011

 

ANGLE plc ("the Company")

 

Geomerics Real-Status deal

 

ANGLE plc, which focuses on the commercialisation of technology and the development of technology-based industry, is pleased to announce that its 35% owned portfolio company Geomerics Limited, which specialises in computer games middleware, has secured a 12% equity stake in Real-Status Limited worth £0.45 million in exchange for the right to use certain of Geomerics' non-core intellectual property.

 

Real-Status targets the $1.3 billion sector of IT dashboard and analysis software. Real-Status is due to launch its first product, which is currently in customer trials, in the second quarter of 2011. Real-Status has today announced completion of a funding round raising £1.2 million to commercialise this product and further develop its business.

 

Real-Status' product creates real-time 3D visualisation of computer networks and overlays performance and business metrics, enabling IT managers and Chief Information Officers to see a virtual model of their entire ICT infrastructure. This facilitates the rapid identification of issues and enables users to organise their network and IT systems to give optimal performance and utilisation. For more information, visit www.real-status.com.

 

The non-core intellectual property licensed to Real-Status is separate from and not dependent on Geomerics' core intellectual property. It was developed separately under a joint project with Intergence, part-funded by the UK Government Technology Strategy Board. Geomerics received grant income of £0.22 million in relation to this development work.

 

The value of the equity holding in Real-Status is based on the value attributed to Real-Status in its third party funding round. The deal generates a profit for Geomerics of £0.45 million. If Real-Status fulfils its potential in the emerging ICT visualisation market, Geomerics' equity holding in Real-Status has the potential to rise substantially in value.

 

 

Royce Murphy, CEO of Real-Status commented:

"We are delighted to have closed the funding round and intellectual property agreement with Geomerics. IT dashboard and analysis software is already a $1.3 billion market, and Real-Status' technology promises break-through products that will display virtual and physical infrastructure together in a scalable way. 2011 is set to be a very successful year for both Real-Status and our, soon to be announced, ICT modelling and visualisation product."

 

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"The Real-Status deal provides Geomerics' shareholders with the potential for additional return without distraction of resources from the core business. Geomerics' business continues to strengthen. Sales of Enlighten, Geomerics' computer games lighting solution, are developing and its corporate partnership with one of the world's leading technology companies is progressing well with the first milestone successfully completed."

 

 

 

For further information:

 

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Collins Stewart Europe Limited

Stewart Wallace

 

0207 523 8350

Scott Harris

Stephen Scott, James O'Shaughnessy, Harry Dee

 

0207 653 0030

 

 

Notes to Editors

 

ANGLE plc

 

Founded in 1994, ANGLE focuses on the commercialisation of technology and the development of technology-based industry. ANGLE creates, develops and advises technology businesses on its own behalf and for its clients.

 

ANGLE's specialist Management services business provides support on a fee-for-service basis to major clients around the world involved in incubation, IP commercialisation, SME innovation and growth and the operation of science & technology parks.

 

ANGLE also owns a portfolio of company holdings with high growth potential in the medical and technology sectors. These have been developed whilst subsidiaries of ANGLE using its proprietary Progeny® process. ANGLE seeks to retain a substantial shareholding in these companies with a view to ongoing returns from dividend, milestone, royalty and capital returns.

 

ANGLE's technology commercialisation skills are of increasing relevance as global economies focus on regeneration, innovation and value added components to their industries. ANGLE's technology skills in IT and software, medical and life sciences, cleantech and renewable energies are directly relevant to major growth markets of the future and are marketed as specialised Management services.

 

ANGLE is quoted on AIM (AGL.L); further information can be found on www.ANGLEplc.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDVLFLFLFFBBE
Date   Source Headline
4th Oct 20195:54 pmRNSHolding(s) in Company
4th Oct 20197:00 amRNSEuropean patent granted for megakaryocyte analysis
13th Sep 20197:00 amRNSUse of Parsortix in head and neck cancer
10th Sep 20197:00 amRNSResearch with Parsortix in prostate cancer
4th Sep 20197:00 amRNSParsortix for Neuroendocrine Analysis in SCLC
29th Aug 20197:00 amRNSInitiation of Ovarian Cancer Study
31st Jul 20197:00 amRNSPrelim Results for the year ended 30 April 2019
22nd Jul 20197:00 amRNSUse of Parsortix for single cell analysis of CTCs
16th Jul 20199:19 amRNSHolding(s) in Company
12th Jul 201910:22 amRNSResult of General Meeting anf Total Voting Rights
28th Jun 20191:37 pmRNSNotice of Preliminary Results and Webcast
28th Jun 20191:08 pmRNSHolding(s) in Company
25th Jun 20195:19 pmRNSResult of Placing
25th Jun 20198:02 amRNSAccelerated bookbuild to raise £18.0m
21st Jun 20197:00 amRNSParsortix used to investigate immunotherapy target
5th Jun 20197:00 amRNSCompletion of Ovarian Cancer Pre-Study
31st May 20197:00 amRNSPositive Results from FDA Clinical Study
26th Apr 20197:00 amRNSIMMUNE SUPPRESSOR CELLS PROMOTE METASTASIS
18th Apr 20197:00 amRNSParsortix used in new cancer assessment technique
12th Apr 20197:00 amRNSLUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
4th Apr 20197:00 amRNSAACR 2019
11th Mar 20197:00 amRNSHolding(s) in Company
7th Mar 20197:00 amRNSENROLMENT COMPLETE FOR FDA CLINICAL STUDY
28th Feb 20197:00 amRNSFIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY
25th Feb 20197:00 amRNSCUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX
11th Feb 20197:00 amRNSResearch into role of immune cells in cancer
31st Jan 20197:00 amRNSInterim Results
29th Jan 20197:00 amRNSNEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS
11th Jan 20192:05 pmRNSSecond Price Monitoring Extn
11th Jan 20192:00 pmRNSPrice Monitoring Extension
11th Jan 201911:05 amRNSSecond Price Monitoring Extn
11th Jan 201911:00 amRNSPrice Monitoring Extension
11th Jan 20199:05 amRNSSecond Price Monitoring Extn
11th Jan 20199:00 amRNSPrice Monitoring Extension
10th Jan 20194:41 pmRNSSecond Price Monitoring Extn
10th Jan 20194:36 pmRNSPrice Monitoring Extension
10th Jan 20194:01 pmRNSBREAKTHROUGH CANCER RESEARCH USING PARSORTIX
9th Jan 20197:00 amRNSNotice of Results
21st Dec 20187:00 amRNSIssue of LTIP Options and Share Options
28th Nov 20187:00 amRNSLEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR
13th Nov 20185:10 pmRNSHolding(s) in Company
5th Nov 20187:00 amRNSAcquisition of outstanding shares
2nd Nov 20182:00 pmRNSPrice Monitoring Extension
1st Nov 20187:00 amRNSAppointment of Dr Jan Groen as NED
30th Oct 20184:21 pmRNSResult of AGM
29th Oct 20187:00 amRNSPARSORTIX SHOWS CAPABILITY TO HARVEST FETAL CELLS
25th Oct 20187:00 amRNSGood Progress with FDA Studies
9th Oct 20187:00 amRNSNotice of AGM
28th Aug 20187:00 amRNSParsortix shows evidence of CTCs in glioblastoma
25th Jul 20187:00 amRNSPreliminary Results for year ended 30 April 2018

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.